Anapen® now approved for 3 seconds
The time for Anapen® adrenaline (epinephrine) autoinjectors to be held in place has now been approved for 3 seconds (reduced from 10 seconds) by the Therapeutic Goods Administration (TGA).
Whilst the time has reduced from 10 to 3 seconds, Anapen® devices have not changed. This reduction is based on data that confirms efficacy and delivery of adrenaline through the 3 second time frame.
All Anapen® devices should now be held in place for 3 seconds, regardless of the instructions on the label. However, if they are held for 10 seconds it will not affect the way that the adrenaline works.
Anapen® devices with the 3 second label are expected to enter pharmacies in Australia from January 2023 onwards. In the meantime, Anapen® devices with a 10 second label can continue to be used, and injected for 3 seconds. Anapen® devices should not be replaced unless they have been used, are just about to expire or have expired.
To access the updated Anapen® versions of the ASCIA Action Plan for Anaphylaxis (red) and ASCIA First Aid Plan for Anaphylaxis (orange) go to www.allergy.org.au/hp/anaphylaxis/ascia-action-plan-for-anaphylaxis
The Anapen® version of the ASCIA Action Plan for Anaphylaxis (red) is provided to people with allergies who have been prescribed Anapen® adrenaline autoinjectors, which have been available on the PBS in Australia since September 2021. In September 2022 the TGA has approved Anapen® to be held in place for 3 seconds (reduced from 10 seconds).
ASCIA anaphylaxis e-training courses have been revised to include the updated Anapen® version of the ASCIA Action Plan for Anaphylaxis and instructions.
Anapen® doses recommended by ASCIA:
- Anapen® 150 (Jr): Children 7.5-20 kg (~1-5 yr)
- Anapen® 300: Adults or children >20kg (>5 yr)
- Anapen® 500: Adults or children >50kg (>12 yr)
This news item was issued on 9 September 2022 and updated on 12 September by Jill Smith, CEO of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body for clinical immunology and allergy in Australia and New Zealand.